Quantum-Si Showcases Protein Sequencing Innovations at Festival of Genomics UK 2025
- Quantum-Si will showcase its Platinum® Pro platform for protein sequencing at the Festival of Genomics UK in January 2025.
- Dr. Richard Broadhead will present advancements in protein sequencing, emphasizing high-resolution characterization and the platform's accessible workflow.
- Quantum-Si aims to bridge genomics and proteomics, enhancing research through innovations like the Protein Barcoding Kit and Library Prep Kit.
Quantum-Si Showcases Innovations in Protein Sequencing at Festival of Genomics UK
Quantum-Si Incorporated, recognized as The Protein Sequencing Company™, is set to participate in the Festival of Genomics UK on January 29–30, 2025. At this prominent event hosted at ExCeL London, Dr. Richard Broadhead, a key figure within the company, will deliver a presentation titled "Advancing Multiomics with Next-Generation Protein Sequencing™: High-Resolution Protein and Proteoform Characterization with an Accessible Workflow." This presentation underscores Quantum-Si’s commitment to revolutionizing the proteomics field through its innovative Platinum® Pro platform, which is designed for single-molecule protein sequencing. This advanced approach significantly enhances the precision of protein identification and the characterization of proteoforms.
The Platinum® Pro platform stands out in its ability to differentiate between various proteoforms that arise from single amino acid variations, alternative splicing, and post-translational modifications. Such distinctions are crucial for correlating genomic data with cellular functions and outcomes. By effectively integrating proteomic data with genomic and transcriptomic information, researchers gain invaluable insights into complex biological pathways and can identify new biomarkers. This capability is particularly timely as the demand for detailed proteomic analyses grows in the context of personalized medicine and targeted therapies.
In addition to highlighting the core functionalities of the Platinum® Pro platform, Dr. Broadhead will also discuss recent advancements that enhance the platform's usability. These innovations include the Protein Barcoding Kit, which improves protein screening efficiency, and the Library Prep Kit, V2, designed for streamlined sample preparation. Moreover, the integrated software of the Platinum® Pro consolidates data generation and analysis, facilitating the seamless integration of proteomics into multiomics workflows. Quantum-Si’s participation at the Festival of Genomics UK signifies its ongoing efforts to bridge the gap between genomics and proteomics, ultimately unlocking new biological insights and accelerating research breakthroughs.
Alongside its technical advancements, Quantum-Si continues to position itself as a leader in the proteomics sector, poised to engage with the broader genomics community at the festival. By fostering collaboration and dialogue, the company aims to enhance research capabilities and drive innovation in the field of multiomics. For more information about Quantum-Si and its cutting-edge Platinum® Pro benchtop instrument, interested parties are encouraged to visit their official website.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…